The markets are rallying and taking everything with it (for the most part). The proximate reason seems to be that the Ukraine crisis did not escalate, which should not be a total surprise as I have been talking down that situation for awhile. That is not to say it could not escalate again but at […]
August 1 Biotech Update
Market was quite week in the pre-market and has recovered from those lows but has seemed to turn lower. Over the near term I think the upside is slightly higher than the downside, although I would not be surprised to see another leg lower before we get the bounce. Over the medium term, I think […]
July 9 Biotech Update
The market was better today but this is not surprising that we get a breather after the two day sell off. The key is what happens in the afternoon and tomorrow. In other words, we cannot know if this is simply a dead cat bounce before more selling or the end of a quick downdraft. […]
June 17 Biotech Update
The sector continues to do well and if the broader market correction holds off we may be making a move to all-time highs but I would remain cautious. In any case, the sector seems healthy at this point despite heading into the summer doldrums and a seasonally weak period. 1. So the one name I […]
May 28 Biotech Update
Of course, there was a storm last night that knocked out the entire internet connection at LSU, so this is going to be later than usual and I have not been able to follow the market at all. I am getting this posted by hook and crook and hope to be back to normal tomorrow. […]
May 8- The Biotech Draft
While there are some stock specific pieces of news, I want to do something a little different today in honor of the NFL draft. I am going to draft my top 10 stocks. This is assuming that I have no positions at all, so this is not what I would be buying now but if […]
May 7 Biotech Update
I feel like a repeating record in that there is nothing really news worthy today and of course I am a certainly repeating myself in terms of the sector selling. I will just highlight some points that I have talked about before but seem germane for today. First, we are looking at a pretty bifurcated […]
May 2 Biotech Update- The Ups and Downs of the Sector
It was a generally good day in terms of news for the sector (with notable exceptions) but the price action was bad. I think this is going to be the probable going forward in that trading will be very choppy and volatile despite positive or negative news. I do not see this trading as changing […]
February 17 Biotech Update- A Presidents Day Bonus
The market is obviously closed today but I wanted to have a brief note because I am not sure I will have time to write anything significant tomorrow. 1. One question that has been in the back of my mind is M&A. I keep expecting to see more as BMY, GILD, PFE, and others have […]
February 12 Biotech Update- Getting Stretched or the Pause that Refreshes?
It seemed more like a treading water day in the market than a directional move, which is again not bad for biotech. It is said that markets do not give you a lot of time to sell at the top or buy at the bottom and to me this means that the sideways trading is […]
December 17 Daily Biotech Update- What did CEMP say and what is wrong with PCYC?
It was a macro day to a certain extent with the broader market down but biotechs certainly underperformed. There were a few islands of strength but for the most part the entire sector was weak and some significantly so. As I have been saying these moves are noise to a certain extent as the price […]
December 11 Biotech Update- Thought from ASH
I am back from ASH and ready to get back to writing the daily updates. There is a lot to cover, so it may take a couple of days. We are in a post-ASH pullback, which is not surprising and the macro selling was not helping either. Many of the biotechs I follow are above […]
ASH 2013 Preview on ALL/CML/MDS/AML
This year’s annual meeting of the American Society of Hematology (ASH13) is highly anticipated for a number of reasons. The first series in our preview covered what to expect in multiple myeloma. Today’s preview will focus on some of the moves going in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), […]
ASH 2013 Preview on Lymphoid Malignancies
This year’s annual meeting of the American Society of Hematology(ASH13) is highly anticipated for a number of reasons. Pharmacyclic’s Ibrutinib could be viewed as one of the several catalysts sparking the biotech sector’s run the past 2 years. They are now within months of receiving approval for 2 indications where they could benefit patient lives […]
October 15- EOD
While this may surprise you (not) but it was another macro driven day (I know you are probably getting as tired of reading that as I am of writing it). Volume also seems to be drying up as investor simply sit on their hands and wait for Washington to get off of their hands. Despite […]
September 25- EOD
A very interesting and odd day in the market today. Overall the market continued its weakness and biotechs were generally down. The market came back and it seemed to turn into a chop fest. I suspected that the CLVS news would have had a more negative impact on biotech sentiment but there did not seem […]
September 12- EOD
Another relatively weak day in biotech land but this is not to say that the market in general was particularly strong. It is not surprising that both the market and biotechs seems to be taking a breather and would also not be surprising to see it last more than a few days. That being said, […]
September 12- EOD
Another relatively weak day in biotech land but this is not to say that the market in general was particularly strong. It is not surprising that both the market and biotechs seems to be taking a breather and would also not be surprising to see it last more than a few days. That being said, […]
September 12- EOD
Another relatively weak day in biotech land but this is not to say that the market in general was particularly strong. It is not surprising that both the market and biotechs seems to be taking a breather and would also not be surprising to see it last more than a few days. That being said, […]
August 1- EOD
Lots of good earnings and conference calls to go through. It is going to take a couple of days to sort through it all so I will try and focus on a couple of companies a day. 1. There was some discussion yesterday about SGEN and the news that the FDA will not add retreatment […]
